Dear Editor,
We read with interest the case 'Successful treatment of refractory Trichomonas vaginalis (TV) infection using intravenous metronidazole'. 1 In this report, Hawkins et al. acknowledge the limited evidence to endorse the use of intravenous metronidazole for treatment of refractory TV but had exhausted all other options. We have also seen a case of recalcitrant TV, which, after numerous oral treatments, responded to a seven-day course of intravenous metronidazole at a dose of 500 mg three times daily (TDS).
Our patient was a 37-year-old Caucasian woman, who presented with a two-week history of green vaginal discharge. On examination, she had copious yellowgreen discharge, florid cervicitis and the classic 'strawberry cervix'. TV was identified on microscopy and confirmed on culture with Hollander's medium. Other sexually transmitted infection (STI) tests were negative for chlamydia, gonorrhoea, HIV and syphilis.
Over the next 11 weeks, she repeatedly attended clinic with ongoing vaginal discharge. She was initially treated with metronidazole 400 mg twice a day (BD) for five days, which was repeated after primary treatment failure. Subsequent treatments included highdose metronidazole (2 g stat metronidazole followed by 400 mg TDS for 14 days), seven days of tinidazole 2 g once daily (OD) and then two weeks of tinidazole 2 g BD. Despite occasional transient symptom resolution, microscopy remained positive for trichomonads. There was no opportunity for reinfection, having abstained from sexual intercourse with her regular male partner. Her partner was appropriately treated.
As Dr Hawkins and colleagues found, escalating treatment in the absence of resistance testing was difficult. After numerous failed therapies, our patient was extremely distressed and now refused to accept any further oral therapy. Admission for intravenous metronidazole 500 mg TDS for one week and 6% nonoxynol-9 pessaries every night for two weeks as detailed by BASHH guidelines for TV (2007 guidelines in place at this time 2 ) was arranged. Due to delays in obtaining nonoxynol-9 pessaries, the patient was treated with intravenous metronidazole alone, for seven days. She tolerated this well, with no gastrointestinal side effects reported. On clinic review two weeks later, the patient's symptoms had resolved, and no TV was found on either microscopy or culture.
Treatment options in the 2014 BASHH guidelines 3 for recalcitrant TV include paromomycin, acetarsol and tinidazole intravaginal preparations to be used in conjunction with oral nitroimidazoles. The evidence base for this is largely from small case numbers, with varying levels of success for intravaginal preparations from 33-92%. 4, 5 These preparations proved extremely difficult to obtain locally, highlighting the rarity of their need for recalcitrant TV treatment. The new guidelines no longer mention the use of intravenous metronidazole, which was the only option acceptable to our patient after weeks of oral therapies.
